Clinical and Molecular Spectrum of Glucose-6-Phosphate Isomerase Deficiency. Report of 12 New Cases

Elisa Fermo1*, Cristina Vercellati1, Anna Paola Marcello1, Anna Zaninoni1, Selin Aytac2, Mualla Cetin2, Ilaria Capolsini3, Maddalena Casale4, Sabrina Paci5, Alberto Zanella1, Wilma Barcellini1 and Paola Bianchi1

1 UOC Ematologia, UOS Fisiopatologia delle Anemie, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 2 Department of Pediatric Hematology, Faculty of Medicine, Hacettepe University, Ankara, Turkey, 3 Pediatric Oncohematology Section with BMT, Santa Maria della Misericordia Hospital, Perugia, Italy, 4 Department of Woman, Child and General and Special Surgery, University of Campania “Luigi Vanvitelli”, Naples, Italy, 5 Dipartimento di Pediatria, ASST Santi Paolo e Carlo, Presidio Ospedale San Paolo Universita’ di Milano, Milan, Italy

Glucose-6-phosphate isomerase (GPI, EC 5.3.1.9) is a dimeric enzyme that catalyzes the reversible isomerization of glucose-6-phosphate to fructose-6-phosphate, the second reaction step of glycolysis. GPI deficiency, transmitted as an autosomal recessive trait, is considered the second most common erythro-enzymopathy of anaerobic glycolysis, after pyruvate kinase deficiency. Despite this, this defect may sometimes be misdiagnosed and only about 60 cases of GPI deficiency have been reported. GPI deficient patients are affected by chronic non-spherocytic hemolytic anemia of variable severity; in rare cases, intellectual disability or neuromuscular symptoms have also been reported. The gene locus encoding GPI is located on chromosome 19q13.1 and contains 18 exons. So far, about 40 causative mutations have been identified. We report the clinical, hematological and molecular characteristics of 12 GPI deficient cases (eight males, four females) from 11 families, with a median age at admission of 13 years (ranging from 1 to 51); eight of them were of Italian origin. Patients displayed moderate to severe anemia, that improves with aging. Splenectomy does not always result in the amelioration of anemia but may be considered in transfusion-dependent patients to reduce transfusion intervals. None of the patients described here displayed neurological impairment attributable to the enzyme defect. We identified 13 different mutations in the GPI gene, six of them have never been described before; the new mutations affect highly conserved residues and were not detected in 1000 Genomes and HGMD databases and were considered pathogenic by several mutation algorithms. This is the largest series of GPI deficient patients so far reported in a single study. The study confirms the great heterogeneity of the molecular defect and provides new insights on clinical and molecular aspects of this disease.

Keywords: red cell disorders, chronic hemolytic anemias, red cell metabolism, glucose-6-phosphate isomerase deficiency, glycolysis
INTRODUCTION

Glucose-6-phosphate isomerase (GPI, EC 5.3.1.9) is a dimeric enzyme that catalyzes the reversible isomerization of glucose-6-phosphate (G6P) to fructose-6-phosphate (F6P), the second reaction step of glycolysis (Kugler and Lakomek, 2000). In addition to the catalytic function of the dimeric enzyme, the monomeric form of GPI has been shown to act as a cytokine, its activities including neuroleukin (Gurney et al., 1986), myofibril-bound serine-protease inhibitor (Cao et al., 2000), autocrine motility factor (Watanabe et al., 1996), and the maturation and differentiation factor (Xu et al., 1996). More recently an unexpected relationship between GPI and phosphatidate phosphatase 1 (PAPI) activity involved in glycolipid biosynthesis has also been reported (Hallér et al., 2010).

Glucose-6-phosphate isomerase deficiency (OMIM 172400), transmitted as an autosomal recessive trait, is considered the second most common erythro-enzymopathy of aerobic glycolysis, after pyruvate kinase deficiency. GPI deficient patients are affected by mild to severe chronic non-spherocytic hemolytic anemia (CNSHA); in rare cases intellectual disability or neuromuscular symptoms have also been reported (Van Biervliet et al., 1975; Kahn et al., 1978; Zanella et al., 1980; Schröter et al., 2015; Manco et al., 2016; Jamwal et al., 2017; Zaidi et al., 2017; Lakomek, 2000; Clarke et al., 2003; Repiso et al., 2006; Zhu et al., 2018). Missense mutations are the most common, but non-sense and splicing mutations have been reported at the nucleotide level (Kugler and Lakomek, 2000; Mojzikova et al., 2018). Missense mutations have been reported in 12 patients affected by GPI deficiency: six new mutations of the GPI gene have been found and characterized of 12 patients affected by GPI deficiency: Kedar et al., 2018; Mojzikova et al., 2018). Missense mutations have been reported at the nucleotide level (Kugler and Lakomek, 2000; Clarke et al., 2003; Repiso et al., 2006; Zhu et al., 2018). Missense mutations are the most common, but non-sense and splicing mutations have been also observed.

In this paper we report the clinical and molecular characterization of 12 patients affected by GPI deficiency: six new mutations of the GPI gene have been found and related to the clinical pattern. Long term follow-up allowed us to describe the clinical spectrum of the GPI deficiency from infancy to adulthood.

PATIENTS AND METHODS

Patients

Twelve patients (eight males and four females), with a median age at admission of 13 years (ranging from 1 to 51) were studied; eight were of Italian origin, two were Turkish, one from Pakistan and one from Romania.

Hematological and Enzyme Assays

Blood samples were collected after obtaining written informed consent from the patients and approval of the Institutional Ethical Committee. For patients under the age of 18, written informed consent was obtained from the parents. All the diagnostic procedures and investigations were performed in accordance with the Helsinki Declaration of 1975. Routine hematological investigations were carried out according to Dacie and Lewis (2001): complete blood count, reticulocyte count, bilirubin, serum ferritin levels, screening for abnormal/unstable hemoglobins, direct antiglobulin test. To exclude red cell membrane disorders, RBC morphology and red cell osmotic fragility tests were evaluated in all cases. When possible EMA binding tests (Bianchi et al., 2012), red cell protein content by SDS–PAGE analyses (Mariani et al., 2008), and RBC deformability analyses by LoRRca MaxSis (Lasers-Assisted Optical Rotational Cell Analyzer, Mechatronics, NL) (Zaninoni et al., 2018) were performed. RBC enzymes activities were determined according to Beutler et al. (1977). The diagnosis of GPI deficiency was made through the exclusion of the most common causes of hemolytic anemia, by the demonstration of a reduced GPI activity in the probands or in the parents, and by the identification of homozygous or compound heterozygous mutations in the GPI gene.

Molecular Analysis

Genomic DNA was extracted from leukocytes collected from peripheral blood, using standard manual methods (Sambrook et al., 1989). The entire coding region and intronic flanking regions of the GPI gene were analyzed by direct sequencing (ABI PRISM 310 Genetic Analyzer, Applied Biosystems, Warrington, United Kingdom) using the Big Dye Terminator Cycle Sequencing Kit (Applied Biosystems, Warrington, United Kingdom).

When available, total RNA was isolated from leukocytes using TRIzol (Life Technologies, Paisley, United Kingdom) and reverse transcribed to cDNA using random hexamer primers and AMV reverse transcriptase. The entire GPI cDNA was amplified by PCR and automatically sequenced. (RefSeq: ENST00000356487, UniProt P06744). Table 1 reports the primers used for molecular analysis.

To clarify the pathogenetic effect of the genotype identified in patient seven and to exclude other concomitant causes of hemolysis, the DNA sample of the patient was

| Table 1 | Primers used for DNA analysis of GPI gene. |
|--------|------------------------------------------|
| 1F     | CGCCACGCGGCCTCGCT             1R | GCCCCGCTCAGACC |
| 2F     | TCTTCTGGAACGCTGCTTG           2R | GAAGGAGTGAAGTCA |
| 3F     | CCGTCTGCTCATATGGGCA           3R | GGATGAGACACCAG |
| 4F     | TGCTAGTGAGATAGGGGCC           4R | CCCCTCCCTAGG |
| 5F     | CCAGGACGCAGGCTCAGGGA         5R | ACAACGAGTCTCAGG |
| 6F     | GTCTGACCTGCTTGGCGGA         6R | CCAGGAGACAGG |
| 7F     | GCACTGCTGACCTGCTGCA         7R | CGCCTCTACATCAG |
| 8F     | CTAGAAGGAAGGATGTGGGCA       8R | ATCCAAGAAGCAG |
| 9F     | CATCACAGACAGGCTCGCT          9R | GCTAGTATGCA |
| 10F    | GTGCCAGACCGGGAGGACG         10R | GCATGATGTCGAG |
| 11F    | GCACCTCTGTTGCAGAAG            11R | GCAAGGATGAGT |
| 12F    | CTGTCGACGAGGCTGCA          12R | AATGGGAGACAGG |
| 13F    | TTACACGGCGCTGCTGATGCA       13R | ACTGCTGACCGAG |
| 14F    | GAGGAGGAGAGGATGTTGCA        14R | GCACAACCTAGCAG |
| 15F    | GAAATGCAGCGGGTCTGCTG        15R | CCGGATGTCATGAG |
| 16F    | AGCTGAGCGCTCAGGCTC          17R | GTGTTATGAGGAGG |
| 18F    | TGAGGAGGAGCCGGCTAATA        18R | CCAGGAGCAGG |

Frontiers in Physiology | www.frontiersin.org 2

May 2019 | Volume 10 | Article 467
further analyzed on an NGS-targeted panel designed by SureDesign software (Agilent Technologies, Santa Clara, CA, United States), containing 40 genes associated with congenital hemolytic anemias. Libraries were obtained by the HaloPlexHS Target Enrichment System Kit and sequenced on a MiSeq platform (Illumina, San Diego, CA, United States).

**RESULTS**

Table 2 reports the main clinical and hematological data in the 12 GPI deficient patients at the time of diagnosis. In 10/12 patients, extensive clinical data, family history, and laboratory data were available, with a median follow-up of 18 years (ranging from 2 to 40 years).

Consanguinity was confirmed in one Turkish patient and suspected in another two families originating from small Italian villages. Despite the onset of anemia reported at birth or early infancy, the median age of diagnosis varied greatly, half of the cases in fact were diagnosed in adulthood (18 to 51 years) (Figure 1). Six patients were misdiagnosed before receiving the correct diagnosis of GPI in this study: the most common diagnostic errors were hereditary spherocytosis (four cases), thalassemia (one case), or G6PD deficiency (one case). None of the patients showed neurological symptoms attributable to GPI deficiency. Growth and intellectual disability were reported only in case 5, affected by phenylketonuria’ (PKU), untreated during infancy. Case 12 had a comitant G6PD deficiency (0.6 IU/gHb; ref. ranges: 7.2–9.6).

All the patients displayed chronic macrocytic anemia before splenectomy, with median Hb levels during follow-up of 9.4 g/dL (range 8–11.3); median VGM 119 fL (84.8–127.8), MCHC 32.1 g/dL (28.6–33), increased absolute reticulocyte number (210 × 10⁹/L, range 113–660) and increased unconjugated bilirubin. Recurrent drastic drops down of Hb levels (median 5.4 g/dL, 2.7–6.2) were reported during infection/aplastic crisis in five patients.

In 8/12 cases, information on iron status was available, serum ferritin levels were increased in most patients (median 353 ng/mL, 90–2356), two of them requiring chelation therapy due to iron overload.

All the patients displayed a normal osmotic fragility and EMA-binding test. RBC morphology, available in 9/12 patients, was unremarkable although not comparable to normal subjects; a few spherocytes, stomatocytes (ranging from 3 to 10%), echinocytes (3 to 4%), rare ovalocytes or target cells were reported. A more compromised RBC morphology was observed in the splenectomized patients (Figure 2). In six patients, RBC deformability was investigated by LoRRca Osmoscan analysis. Interestingly, all the them showed an altered enlarged Osmoscan curve associated with significantly increased Omin (median 156, range 126–176, p < 0.001) and, even more, Ohyper (median 527, range 439–579, p < 0.001). EImax and AUC values were decreased compared to the controls (Figure 3).

All the patients but one displayed a reduced GPI activity (from 10 to 40% of low normal reference range). In case 8, who showed
normal GPI activity, the diagnosis was reached by studying the GPI activity in the parents.

**Glucose-6-Phosphate Isomerase Deficiency in Infancy**

No intrauterine growth retardation and/or fetal distress were observed in this series of patients prior to birth. Information on the neonatal period was available in 11 patients. Five of them displayed anemia at birth, the remaining six in early infancy (all before 3 years of age). Neonatal jaundice was present in five patients, three of whom required exchange transfusion. During childhood all patients but two needed blood transfusions: three of them regularly with a transfusion interval of 4 to 8 weeks. The other patients were occasionally transfused in concomitance of hemolytic crises due to infections.

**Glucose-6-Phosphate Isomerase Deficiency and Splenectomy**

Six patients were splenectomized, all of them before the diagnosis of GPI deficiency. Only one patient recovered from anemia; in the remaining cases, although resulting only in a slight increase of Hb levels (0.5–1 g/dL), splenectomy greatly reduced or even eliminated transfusion requirement.

Interestingly, in some patients a considerable increase of the reticulocyte counts and unconjugated bilirubin was observed after splenectomy. No thrombotic events have been reported in the six splenectomized patients, since their surgeries.

**Molecular Heterogeneity of Glucose-6-Phosphate Isomerase Deficiency**

Table 3 reports the biochemical and molecular data of the GPI deficient patients. Thirteen different missense mutations were found in the GPI gene, six of them never described before (c.145G>C, p.Gly49Arg; c.269T>G, p.Ile90Thr; c.307C>G, p.Leu103Val; c.311 G>A, p.Arg104Gln; c.839T>G, p.Ile280Ser; c.921C>A, p.Phe307Leu) (Figure 4).

All the new mutations affect highly conserved residues, and were predicted to have pathogenic effects by Polyphen-2, Mutation Taster, and M-CAP (Table 4).

Seven patients were homozygote and four compounds heterozygotes for two different mutations. In patient 7, despite the sequencing of the entire GPI codifying region, intronic flanking regions and promoter, we were able to find only one mutation at the heterozygous level (p.Arg472His), transmitted by the mother. In addition, we detected the polymorphism c.489A>G [synonymous variant p.Gly163=, rs1801015, GMAF 0.20070 (G), ExAC 0.11116], transmitted by the father. No other pathogenetic mutations were detected by the NGS targeted sequencing of 40 genes associated with congenital hemolytic anemias, confirming that GPI deficiency was the only cause of anemia in this patient. cDNA analysis in the proband and his parents revealed a loss of heterozygosity, with only the maternal allele present at the cDNA level, suggesting that the paternal allele was not expressed or rapidly degraded. Despite this, we did not find a difference in clinical severity in these patients with respect to the other GPI patients carrying two missense mutations.

**DISCUSSION**

The present cohort of GPI deficient patients represents the largest series so far described in a single study, collecting retrospective information and follow-up data over a median period of 18 years. All the cases were never reported before, consistently increasing the number of GPI patients reported.
allow the simultaneous analysis of multiple genes associated to the coming years due to the advent of new NGS technologies that exact diagnosis is often delayed. clinical presentation with other congenital hemolytic anemias, an 2018; Sonaye et al., 2018). Moreover, due to the similarity in some rare disorders for which specific tests are not considered few specialized centers, or because of the lack of knowledge about lack of availability of the enzymatic assay, performed only in a some rare/very rare hemolytic anemias. At least three additional GPI-deficient patients have been reported in the literature in the last 2 years using these technologies (Jamwal et al., 2017; Kedar et al., 2018; Russo et al., 2018).

The possibility to evaluate a consistent group of patients from infancy to adulthood allowed us to describe the clinical picture of GPI deficiency, which is characterized by the onset of chronic macrocytic anemia at birth or early infancy, reticulocytosis, jaundice and splenomegaly associated with mild hepatomegaly; in all the patients in which the information was available, pregnancy was uneventful with normal growth development. This clinical pattern is in line with cases previously described by our group (Baronciani et al., 1996); however, in some patients a more severe clinical presentation, i.e., hydrops fetalis, has been reported (Ravindranath et al., 1987; Adama van Scheltema et al., 2015).

Neuromuscular impairment or mental retardation are rare complication sometimes reported in GPI deficiency (Van Biervliet et al., 1975; Kahn et al., 1978; Zanella et al., 1980; Shalev et al., 1993; Kugler et al., 1998; Jamwal et al., 2017), as well as in other glycolytic enzyme defects caused by ubiquitously expressed genes (i.e., phosphoglycerate kinase deficiency, phosphofructokinase deficiency or triosephosphate isomerase deficiency). The link between GPI deficiency and neuromuscular dysfunction has not been fully established, and has been attributed to the fact that the monomeric form of GPI is identical to neuroleukin (NLK), a neurotrophic factor that supports the survival of embryonic spinal neurons, skeletal neurons and sensory neurons; however, the proposed hypothesis on the molecular mechanism leading to a neuromuscular dysfunction are in some cases contradictory (Kugler et al., 1998; Repiso et al., 2005). Actually, only three GPI deficient cases with neurological impairment were characterized at molecular level: two of them were homozygous for mutations p.Arg347Cys and p.Arg347His, respectively, and one was compound heterozygous for mutations p.His20Pro and p.Leu339Pro (Beutler et al., 1997; Kugler et al., 1998; Jamwal et al., 2017). A large number of cases with mutations affecting amino acid Arg347 (including two in our series) have been reported with only hematological involvement, suggesting that other possible confounding factors, independent from enzyme deficiency itself, such as kernicterus (Jamwal et al., 2017) or other genetic defects in consanguineous families, may contribute to the clinical phenotype.

A long follow-up time allowed us to shine light on other possible features of GPI deficiency not yet clearly reported in literature: (a) increased sensitivity to infections that result in a dramatic drop-down of hemoglobin levels persisting also in adults, (b) a low response to splenectomy resulting only in a slight increase of Hb levels, however eliminating or reducing the transfusion requirement in all patients, (c) a tendency to increase the reticulocyte number after splenectomy, probably due to selective sequestration of younger GPI defective erythrocytes by the spleen as previously hypothesized in PK deficiency (Mentzer et al., 1971; Matsumoto et al., 1972).

Increased sensitivity to infections was reported in other GPI cases (Helleman and Van Biervliet, 1976; Repiso et al., 2006; Manco et al., 2016; Kedar et al., 2018), making this aspect relevant
As previously reported, GPI-deficient red cells produce an altered Osmoscan profile (LoRRca analyzer), characterized by a right enlarged opened curve (Zaninoni et al., 2018). These findings, which result in a statistically significative increase of Ohyper values, offer an initial laboratory screen for patients with this rare enzyme defect. A possible explanation may reside in an increased red cell volume, or a cellular overhydrated state resulting in cell swelling of an origin not yet investigated. Increased thrombotic risk after splenectomy, clearly demonstrated in hereditary xerocytosis, and in overhydrated stomatocytosis (Fermo et al., 2017; Iolascon et al., 2017) has recently been reported in some enzyme defects i.e., pyruvate kinase deficiency) (Grace et al., 2018). No thrombotic events have been reported in the analyzed series, or in the GPI deficient
cases reported in literature; however, we cannot exclude that this information might be lost at follow up.

Information on iron status and erythropoietic activity in GPI deficiency is scant, although it is known that iron overload may frequently occur in other more common glycolytic enzymopathies as a consequence of various factors, including hyperhaemolysis or ineffective erythropoiesis. Only iron stores (ferritin levels) were available in the present series and found to be elevated in four of seven patients, underlying the need of monitoring iron status in this disease.

Glucose-6-phosphate isomerase deficiency shows a wide molecular heterogeneity with more than 40 mutations in the GPI gene currently listed in the Human Gene Mutation Database1. Most of them are missense, covering about 93% of the total mutations identified, with only a few splicing, nonsense or frameshift mutations (Kugler and Lakomek, 2000; Manco et al., 2016). This is in line with the findings in our series, where all the different mutations identified were missense. Despite this, loss of heterozygosity at the cDNA level in patient 7, who did not show the second causative mutation, neither by Sanger sequencing nor by NGS targeted sequencing, may suggest that in GPI deficiency some drastic molecular abnormalities escape the conventional screening techniques. Interestingly, patient 7 carried the paternal allele on the silent polymorphic variant c.489A>G (p.Gly163=), that is located in the third nucleotide of exon 6. Although we did not perform functional in vitro analysis of this silent mutation, we cannot exclude that the variant, although polymorphic, may interfere with the normal splicing, resulting in an unstable mRNA, rapidly degraded.

Despite the molecular heterogeneity, some recurrent mutations have been identified in GPI deficiency. This is the case of missense mutations affecting the amino acid Arg347, here detected in two brothers of Turkish origin (c.1040G>A, p.Arg347His) and already reported in literature in other unrelated patients of different ethnical origins (Walker et al., 1993; Repiso et al., 2006; Lin et al., 2009); another mutation at the same codon (c.1039G>T, p.Arg347Cys) has also been described (Xu and Beutler, 1994; Lin et al., 2009), suggesting the presence of a mutational hotspot (Repiso et al., 2005). Arg347 is a highly conserved residue (GERP 5.65), falling in the region responsible for GPI dimerization. It has been hypothesized that a mutation in these residues causes a loss of GPI capability to dimerize, making the enzyme more susceptible to thermolability; actually, kinetic studies performed in a mutant enzyme from an homozygous p.Arg347His patient, showed that the Km for G6P and for F6P were not altered, but the thermostability was drastically reduced (Walker et al., 1993; Repiso et al., 2006; Lin et al., 2009).

Polymorphisms at the same codon (c.1039G>T, p.Arg347Cys) have also been described (Xu and Beutler, 1994; Lin et al., 2009), suggesting the presence of a mutational hotspot (Repiso et al., 2005). Arg347 is a highly conserved residue (GERP 5.65), falling in the region responsible for GPI dimerization. It has been hypothesized that a mutation in these residues causes a loss of GPI capability to dimerize, making the enzyme more susceptible to thermolability; actually, kinetic studies performed in a mutant enzyme from an homozygous p.Arg347His patient, showed that the Km for G6P and for F6P were not altered, but the thermostability was drastically reduced (Repiso et al., 2005).

Different than expected and previously reported in literature (Walker et al., 1993; Repiso et al., 2005) the cases in this series carrying mutation p.Arg347His did not show a drastic reduction

---

1 www.hgmd.cf.ac.uk

---

| TABLE 3 | Biochemical and molecular data of the GPI deficient patients. |
|---------|-----------------|-------------------|-----------------|
| Pt | GPI activity (IU/gHb) | Residual activity % | Mutation | Effect |
| 1 | 6 | 10% | c.145G>C/c.921C>A | p.Gly49Arg/p.Phe307Leu |
| 2 | 10.5 | 19% | c.311G>A/c.584C>T | p.Arg104Gln/p.Thr195ile |
| 3 | 18 | 32% | c.307C>G/c.307C-G | p.Leu103Val/p.Leu103Val |
| 4 | 15.7 | 28% | c.309G>A/c.1009G>A | p.Gly101Met/p.Ala337Thr |
| 5 | 13.3 | 24% | c.1009G>A/c.1009G>A | p.Ala337Thr/p.Ala337Thr |
| 6 | 14.3 | 26% | c.584C>T/c.584C>T | p.Cys195ile/p.Cys195ile |
| 7 | 16 | 29% | c.489A>G (rs1801015)/c.1415G>A | p.Leu320Phe/p.Leu320Phe |
| 8 | 54.6 | 98% | c.269T>C/c.1066G>A | p.Asp95Asn |
| 9 | 22 | 40% | c.1040G>A/c.1040G>A | p.Asp347His/p.Asp347His |
| 10 | 17 | 30% | c.1040G>A/c.1040G>A | p.Asp347His/p.Asp347His |
| 11 | 20.2 | 36.5% | c.839T>G/c.839T>G | p.Ile280Ser/p.Ile280Ser |
| 12 | 4.8 | 9% | c.1574T>C/c.1574T>C | p.Ile525Thr/p.Ile525Thr |

Percentage of residual GPI activity was calculated on the lower reference value. New mutations are reported in bold.

| TABLE 4 | List of new variants identified. |
|---------|-----------------|-------------------|-----------------|
| HGVS coding | HGVS protein | GPI structure | Exon | Status | Polyphen-2 | M-CAP | MAF1000G | MAF ExAC | RefSeqID |
| c.145G>C | Gly49Arg | Lj1-1j2 | 2 | Het | 1.000 (0.00; 1.00) D | 0.385 P | – | – | – |
| c.269T>C | p.Ile90Thr | Lx6-Turn | 3 | Het | 1.000 (0.00; 1.00) D | 0.343 P | – | – | – |
| c.307C>G | p.Leu103Val | a8 | 4 | Hom | 0.649 (0.87; 0.91) PD | 0.479 P | – | – | – |
| c.311G>A | p.Arg104Gln | Lx8-b4 | 4 | Het | 0.544 (0.88; 0.91) PD | 0.577 P | – | – | – |
| c.839T>G | p.Ile280Ser | a21 | 10 | Hom | 1.000 (0.00; 1.00) D | 0.611 P | – | – | – |
| c.921C>A | p.Phe307Leu | a23 | 12 | Het | 1.000 (0.00; 1.00) D | 0.383 P | A = 0.000008 rs754782152 | – | – | – |

Polyphen-2 analysis (HumDiv): PD, possibly damaging; D, probably damaging; in bracket sensitivity, specificity; M-CAP: P, possibly pathogenic (ref. Jagadeesh et al., 2016). Recommended pathogenicity threshold: Polyphen-2 > 0.8 (with misclassified pathogenetic variants 31%); M-CAP > 0.25 (with misclassified pathogenetic variants 5%).
of GPI activity (30–40% of residual activity vs. 18% reported by others); this could be explained by technical variability in the enzymatic assay, or by the very high number of reticulocytes found in our patients at the time of the assay, which may display an higher enzyme activity than mature red cells (Beutler et al., 1977). Other recurrent mutations found in this series were p.Thr195Ile and p.Val101Met, already reported in Italian patients by Baronciani et al. (1996).

CONCLUSION

In conclusion, the study confirms the great heterogeneity of the molecular defect and provides new insights on clinical and molecular aspects of this disease.

REFERENCES

Adama van Scheltema, P. N., Zhang, A., Ball, I. M., Steggerda, S. J., van Wijk, R., Fransen van de Putte, D. E., et al. (2015). Successful treatment of fetal hemolytic disease due to glucose phosphate isomerase deficiency (GPI) using repeated intratranferine transfusions: a case report. Clin. Case Rep. 3, 862–865. doi: 10.1002/crre.3358

Baronciani, L., Zanella, A., Bianchi, P., Zappa, M., Alfinito, F., Iolascon, A., et al. (1996). Study of the molecular defects in glucose phosphate isomerase-deficient patients affected by chronic hemolytic anemia. Blood 88, 2306–2310.

Beutler, E., Blume, K. G., Kaplan, J. C., Lohr, G. W., Ramot, B., and Valentine, W. N. (1977). International Committee for Standardization in Haematology: recommended methods for red-cell enzyme analysis. Br. J. Haematol. 35, 331–340. doi: 10.1111/j.1365-2141.1977.tb00589.x

Beutler, E., West, C., Britton, H. A., Harris, J., and Forman, L. (1997). Glucosephosphate isomerase (GPI) deficiency mutations associated with hereditary nonspherocytic hemolytic anemia (HNSHA). Blood Cells Mol. Dis. 23, 402–409. doi: 10.1006/bcmd.1997.0157

Bianchi, P., Fermo, E., Glader, B., Kanno, H., Agarwal, A., Barcellini, W., et al. (2018). Addressing the diagnostic gaps in pyruvate kinase deficiency: consensus recommendations on the diagnosis of pyruvate kinase deficiency. Am. J. Hematol. [Epub ahead of print].

Bianchi, P., Fermo, E., Vercellati, C., Marcello, A. P., Porretti, L., Corteleezi, L., et al. (2012). Diagnostic power of laboratory tests for hereditary spherocytosis: a comparison study in 150 patients grouped according to molecular and clinical characteristics. Haematologia 97, 516–523. doi: 10.3324/haematol.2011.052845

Burger, N. C. M., van Wijk, R., Bresters, D., and Schell, E. A. (2018). A novel mutation of glucose phosphate isomerase (GPI) causing severe neonatal anemia due to GPI deficiency. J. Pediatr. Hematol. Oncol. 41, e186–e189. doi: 10.1097/MPH.0000000000001393

Cao, M. J., Osatomi, K., Matsude, R., Ohkubo, M., Hara, K., and Ishihara, K. (2000). Purification of a novel serine proteinase inhibitor from skeletal muscle of white croaker (Argyrosomus argentatus). Biochem. Biophys. Res. Commun. 272, 485–489. doi: 10.1006/bbrc.2000.2803

Clarke, J. L., Vulliamy, T. J., Roper, D., Mesbah-Namin, S. A., Wild, B. I., Walker, J. I., et al. (2003). Combined glucose-6-phosphate dehydrogenase and glucosephosphate isomerase deficiency can alter clinical outcome. Blood Cells Mol. Dis. 30, 258–263. doi: 10.1016/s1079-9796(03)00227-5

Dacie, J. V., and Lewis, S. M. (2001). Practical Haematology, 9th Edn. London: Churchill Livingstone.

Fermo, E., Vercellati, C., Marcello, A. P., Zaninoni, A., van Wijk, R., and Mirra, N. (2017). Hereditary xerocytosis due to mutations in PIEZO1 gene associated with hemolytic anemia of Argyrosomus argentatus (p.Arg347His) causing hemolysis in an Indian infant. Clin. Chim. Acta 468, 81–84. doi: 10.1016/j.cca.2017.02.012

Kahn, A., Buc, H. A., Girot, R., Cotteau, D., and Griscelli, C. (1978). Molecular and functional anomalies in two new mutant glucose-phosphate-isomerase variants with enzyme deficiency and chronic hemolyosis. Hum. Genet. 40, 293–304. doi: 10.1007/bf00272190

Kedar, P. S., Gupta, V., Dongerdiye, R., Chiddarwar, A., Warang, P., and Madkikar, M. R. (2018). Molecular diagnosis of unexplained haemolytic anaemia using targeted next-generation sequencing panel revealed (p.Ala337Thr) novel mutation in GPI gene in two Indian patients. J. Clin. Pathol. 2019, 81–85. doi: 10.1136/jclinpath-2018-205420

Kugler, W., and Lakomek, M. (2000). Glucose-6-phosphate isomerase deficiency, Baillière’s Best. Pract. Res. Clin. Haematol. 13, 89–101. doi: 10.1053/beh.1999.0059

Lin, H. Y., Kao, Y. H., Chen, S. T., and Meng, M. (2009). Effects of inherited mutations on catalytic activity and structural stability of human glucose-6-phosphate isomerase expressed in Escherichia coli. Bioc hem. Biophys. Acta 1794, 315–323. doi: 10.1016/j.bbabio.2008.11.004

Manco, L., Bento, C., Victor, B. L., Pereira, J., Relvas, L., Brito, R. M., et al. (2016). Hereditary nonspherocytic hemolytic anemia caused by red cell glucose-6-phosphate isomerase (GPI) deficiency in two Portuguese patients: clinical features and molecular study. Blood Cells Mol. Dis. 60, 18–23. doi: 10.1016/j.bcmd.2016.06.002

AUTHOR CONTRIBUTIONS

EF and PB performed the molecular analysis, analyzed the results, prepared and revised the manuscript. CV, AM, and AnZ performed the hematologic and biochemical investigations. SA, MuC, IC, MaC, SP, AIz, and WB performed the patient follow-up and revision of the manuscript.

FUNDING

The study was supported by the Fondazione IRCCS “Ca’ Granda” Ospedale Maggiore Policlinico Milano, Project number RC 175/04, 2015–2017.
Mariani, M., Barcellini, W., Vercellati, C., Marcello, A. P., Fermo, E., Pedotti, P., et al. (2008). Clinical and hematologic features of 300 patients affected by hereditary spherocytosis grouped according to the type of the membrane protein defect. *Haematologica* 93, 1310–1317. doi: 10.3324/haematol.12546

Matsumoto, N., Ishihara, T., Nakashima, K., Miwa, S., Uchino, F., and Kondo, M. (1972). Sequestration and destruction of reticulocytes in the spleen in pyruvate kinase deficiency hereditary non-spherocytic hemolytic anemia. *Nippon Ketsueki Gakkai Zasshi* 35, 525–537.

Mentzer, W. C. Jr., Badhner, R. L., Schmidt-Schonbeth, H., Robinson, S. H., and Matsumoto, N., Ishihara, T., Nakashima, K., Miwa, S., Uchino, F., and Kondo, M. (1972). Sequestration and destruction of reticulocytes in the spleen of patients with pyruvate kinase deficiency hereditary non-spherocytic hemolytic anemia. *J. Clin. Invest.* 5, 688–699.

Mojzikova, R., Korakova, P., Holub, D., Saxova, Z., Pospisilova, D., Prochazkova, D., et al. (2018). Two novel mutations (p.Ser160Pro and p.Arg472Cys) causing glucose-6-phosphate isomerase deficiency are associated with erythroid dysplasia and inappropriately suppressed hepcidin. *Blood Cells Mol. Dis.* 69, 23–29. doi: 10.1016/j.bcmd.2017.04.003

Ravindranath, Y., Paglia, D. E., Warrier, L., Valentine, W., Nakatani, M., and Brockway, R. A. (1987). Glucose phosphate isomerase deficiency as a cause of hydrops fetalis. *N. Engl. J. Med.* 316, 258–261. doi: 10.1056/nejm198701293160506

Repiso, A., Oliva, B., Vives Corrons, J. L., Carreras, J., and Climent, F. (2005). Glucose phosphate isomerase deficiency: enzymatic and familial characterization of Arg346His mutation. *Biochim. Biophys. Acta* 1740, 467–471. doi: 10.1016/j.bbadis.2004.10.008

Repiso, A., Oliva, B., Vives-Corrons, J. L., Beutler, E., Carreras, J., and Climent, F. (2006). mRed cell glucose phosphate isomerase (GPI): a molecular study of three novel mutations associated with hereditary nonspherocytic hemolytic anemia. *Hum. Mutat.* 27:1159. doi: 10.1002/humu.9466

Russo, R., Andolfi, I., Manna, F., Gambale, A., Marra, R., Rosato, B. E., et al. (2018). Multi-genie panel testing improves diagnosis and management of patients with hereditary anemias. *Am. J. Hematol.* 93, 672–682. doi: 10.1002/ajh.25058

Sambrook, J., Fritsch, E. F., and Maniatis, T. (1989). *Molecular Cloning: A Laboratory Manual*. New York, NY: Cold Spring Harbor Laboratory Press.

Schröter, W., Eber, S. W., Bardosi, A., Gahr, M., Gabriel, M., and Sitzmann, F. C. (1985). Generalised glucosephosphate isomerase (GPI) deficiency causing haemolytic anaemia, neuromuscular symptoms and impairment of granulocytic function: a new syndrome due to a new stable GPI variant with diminished specific activity (GPI Homburg). *Eur. J. Paediatr.* 144, 301–305. doi: 10.1007/BF00441768

Shalev, O., Shalev, R. S., Forman, L., and Beutler, E. (1993). GPI mount scopus ± a variant of glucose-phosphate isomerase deficiency. *Ann. Hematol.* 67, 197–200. doi: 10.1007/bf01695868

Sonaye, R., Sombans, S., and Ramphul, K. (2018). A case report of congenital non-spherocytic hemolytic anemia in a patient from India. *Cureus* 2018:e2478. doi: 10.7759/cureus.2478

Van Biervliet, J. P., Van Milligen-Boersma, L., and Staal, G. E. (1975). A new variant of glucosephosphate isomerase deficiency (GPI-Utrecht). *Clin. Chim. Acta* 65, 157–165. doi: 10.1016/0009-8981(75)90103-5

Walker, J. I. H., Layton, D. M., Bellingham, A. J., Morgan, M. J., and Faik, P. (1993). DNA sequence abnormalities in human glucose 6-phosphate isomerase deficiency. *Hum. Mol. Gen.* 2, 327–329. doi: 10.1093/hmg/2.3.327

Walker, J. I. H., Morgan, M. J., and Faik, P. (1995). Structure and organization of the human glucose phosphate isomerase gene (GPI). *Genomics* 29, 261–265. doi: 10.1006/geno.1995.1241

Warang, P., Kedar, P., Ghosh, K., and Colah, R. B. (2012). Hereditary non-spherocytic hemolytic anemia and severe glucose phosphate isomerase deficiency in an Indian patient homozygous for the L487F mutation in the human GPI gene. *Int. J. Hematol.* 96, 263–267. doi: 10.1007/s11238-012-1122-x

Watanabe, H., Takehana, K., Date, M., Shinozaki, T., and Raz, A. (1996). Tumor cell autocrine motility factor is the neuroleukin/phosphohexose isomerase polypeptide. *Cancer Res.* 56, 2960–2963.

Xu, W., and Beutler, E. (1994). The characterization of gene mutations for human glucose phosphate isomerase deficiency associated with chronic haemolytic anemia. *J. Clin. Invest.* 94, 2326–2329. doi: 10.1172/jci17597

Xu, W., Seiter, K., Feldman, E., Ahmed, T., and Chiao, J. W. (1996). The differentiation and maturation mediator for human myeloid leukemia cells shares homology with neuroleukin or phosphoglucose isomerise. *Blood* 87, 4502–4506.

Zaidi, A. U., Kedar, P., Koduri, P. R., Goyette, G. W. Jr., Buck, S., Paglia, D. E., et al. (2017). Glucose phosphate isomerase (GPI) Tadikonda: characterization of a novel Pro340Ser mutation. *Pediatr. Hematol. Oncol.* 34, 449–454. doi: 10.1080/08880018.2017.1383541

Zanella, A., Izzo, C., Rebullia, P., Ferroni, L., Mariani, M., Canestri, G., et al. (1980). The first stable variant of erythrocyte glucose-phosphate isomerase associated with severe hemolytic anemia. *Am. J. Hematol.* 9, 1–11. doi: 10.1002/ajh.2830090102

Zaninoni, A., Fermo, E., Vercellati, C., Consonni, D., Marcello, A. P., Zanella, A., et al. (2018). Use of laser assisted optical rotational cell analyzer (LoRRca MaxSis) in the diagnosis of RBC membrane disorders, enzyme defects, and congenital dyserythropoietic anemias: a monocentric study on 202 patients. *Front. Physiol.* 9:451. doi: 10.3389/fphys.2018.00451

Zhu, X., Petrovski, S., Xie, P., Ruzzo, E. K., Lu, Y. F., McSweeney, K. M., et al. (2015). Whole-exome sequencing in undiagnosed genetic diseases: interpreting 119 trios. *Genet. Med.* 17, 774–781. doi: 10.1038/gim.2014.191

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2019 Fermo, Vercellati, Marcello, Zaninoni, Aytaç, Cetin, Capololini, Casade, Pucci, Zanella, Barcellini and Bianchi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.